为不断完善三博脑科医院管理集团股份有限公司（以下简称"公司"）产业链， 扩大公司业务规模，提升医疗服务技术水平和核心竞争力，同时为充分利用资本 市场平台优势，借助专业投资机构的管理水平和投资经验，公司作为有限合伙人 与基金管理人达孜德联投资管理有限公司、普通合伙人上海合创博联管理咨询合 伙企业（有限合伙）及其他有限合伙人共同投资设立上海德联博健创业投资合伙 企业（有限合伙）（以下简称"基金"），具体内容详见公司于 2025 年 8 月 22 日 在巨潮资讯网披露的《关于与专业投资机构共同投资认购基金份额的公告》（公 告编号：2025-029）。 近日，达孜德联投资管理有限公司已根据《证券投资基金法》和《私募投资 基金监督管理暂行办法》等法律法规的要求，在中国证券投资基金业协会完成对 基金的备案，并取得私募投资基金备案证明。 一、私募投资基金备案信息 证券代码：301293 证券简称：三博脑科 公告编号：2025-039 三博脑科医院管理集团股份有限公司 关于参与设立的投资基金完成私募基金备案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 1 基金名称： ...

Group 1 - The company has several new hospital campuses under development, with specific updates on each location [1] - The Kunming Sanbo new campus officially commenced operations in May 2023 [1] - The Xi'an Sanbo campus has completed construction and obtained medical practice licenses, with plans for opening at a later date [1] - The Hunan Sanbo campus is still under construction [1] - The Beijing Sanbo new campus is expected to complete its overall relocation and commence operations in the first quarter of 2026 [1]

Core Insights - The medical services sector experienced a slight increase of 0.29% on September 16, with Chengda Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Medical Services Sector Performance - Chengda Pharmaceutical (301201) closed at 33.32, with a significant increase of 15.25% and a trading volume of 157,100 shares, amounting to a transaction value of 508 million yuan [1] - Haocen Medical (002622) saw a rise of 10.10%, closing at 4.25 with a trading volume of 993,200 shares, totaling 409 million yuan [1] - Aoyang Health (002172) increased by 10.00%, closing at 4.73 with a trading volume of 87,500 shares, amounting to 41.39 million yuan [1] - Bid Pharma (688073) rose by 6.48%, closing at 74.73 with a trading volume of 26,000 shares, totaling 192 million yuan [1] - Yikang Biological (688046) increased by 5.56%, closing at 19.75 with a trading volume of 79,600 shares, amounting to 158 million yuan [1] - Other notable performers include Haoyuan Pharmaceutical (688131) with a 4.44% increase, closing at 78.28, and Xinlicheng (002219) with a 3.46% increase, closing at 2.39 [1] Fund Flow Analysis - The medical services sector saw a net outflow of 228 million yuan from institutional investors, while retail investors contributed a net inflow of 59.64 million yuan [3] - Speculative funds recorded a net inflow of 168 million yuan into the sector [3]

中信证券股份有限公司 关于三博脑科医院管理集团股份有限公司 2025年半年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：三博脑科 | | --- | --- | | 保荐代表人姓名：赵陆胤 | 联系电话：010-60838145 | | 保荐代表人姓名：王栋 | 联系电话：010-60833110 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 无 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不 限于防止关联方占用公司资源的制度、募集资金 | 是 | | 管理制度、内控制度、内部审计制度、关联交易 | | | 制度） | | | （2）公司是否有效执行相关规章制度 | 是，根据三博脑科内部控制自我评价报告，发 | | | 行人有效执行了相关规章制度。 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 6次：保荐人每月查询公司募集资 ...

北京市中伦律师事务所 关于三博脑科医院管理集团股份有限公司 2025 年第一次临时股东会的 法律意见 二〇二五年九月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 北京市中伦律师事务所 关于三博脑科医院管理集团股份有限公司 2025 年第一次临时股东会的 法律意见 致：三博脑科医院管理集团股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受三博脑科医院管理集团股份 有限公司（以下简称"公司"）委托，指派本所律师列席公司 2025 年第一次临时 股东会（以下简称"本次股东会"），并出具本法律意见 ...

证券代码：301293 证券简称：三博脑科 公告编号：2025-038 三博脑科医院管理集团股份有限公司 2025 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 （1）现场会议时间：2025 年 9 月 11 日下午 15:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 9 月 11 日上午 9:15-9:25、9:30-11:30，下午 13:00-15:00；通过深 圳证券交易所互联网投票系统投票的具体时间为：2025 年 9 月 11 日 9:15-15:00 期间的任意时间。 4、会议召开方式：现场投票与网络投票相结合的方式。 5、现场会议召开地点：北京市海淀区世纪金源香山商旅酒店 831 栋公司会 议室 6、会议主持人：本次会议由公司董事长张阳先生主持。 （二）会议出席情况 1、股东出席的总体情况： 通过现场和网络投票的股东 315 ...

Core Viewpoint - Sanbo Neuroscience (301293.SZ) continues to invest in the brain science sector through fund participation, aiming to enhance its industry chain and clinical capabilities [1][2]. Investment Activities - The company plans to invest 57 million yuan in the establishment of Tianjin Yuanming Haihe Brain Science Venture Capital Partnership, focusing on brain science investments [2]. - The total fundraising target for this fund is 300 million yuan, concentrating on clinical advantages in brain disease diagnostics, treatment, health management, and medical information [2]. - In August, the company announced investments of 87 million yuan and 10 million yuan in two other funds, totaling 154 million yuan in investments within a month [3]. Company Performance - Sanbo Neuroscience has shown continuous growth since its listing in 2023, with revenue reaching 1.313 billion yuan and a net profit of 78.238 million yuan, marking increases of 22.73% and 23.31% year-on-year, respectively [4]. - For 2024, the company expects revenue to grow by 8.84% to 1.429 billion yuan, with net profit increasing by 34.24% to 105 million yuan, marking the first time net profit exceeds 100 million yuan [4]. - In the first half of 2025, the company achieved revenue of 827 million yuan, a year-on-year increase of 17.54%, with net profit reaching 69.696 million yuan, also a new mid-year high [5]. Regional Revenue Breakdown - The main revenue sources for the company are from the Southwest and North China regions, contributing 51.63% and 31.6% of total revenue, respectively [5].

Group 1 - Dematech won a 900 million yuan overseas smart logistics project from a well-known e-commerce giant in Latin America, focusing on intelligent logistics cross-belt sorting systems and related services [1] - Kang En Bei received approval for the registration of short-term financing bonds and medium-term notes, with a total registration amount of 1 billion yuan, valid for two years [1][2] - Zhi Xiang Jin Tai's GR1803 injection for systemic lupus erythematosus clinical trial has been approved by the National Medical Products Administration [2] Group 2 - Jin Da Wei's subsidiary received approval for a veterinary drug product, pyridone, valid from September 3, 2025, to September 2, 2030 [4] - Fu Li Wang's subsidiary plans to invest 500 million yuan in a high-end wire material project, focusing on high-strength prestressed steel strands for various applications [5] - He Li Biological's subsidiary's Class III medical device registration application has been accepted, focusing on natural bone repair materials [12] Group 3 - Lin Yang Energy won a 244 million yuan metering equipment project from Southern Power Grid, expected to positively impact its 2025 and 2026 performance [20] - Sanxia Water plans to absorb its wholly-owned subsidiary, Chongqing Changdian United Energy, with all assets and liabilities to be inherited by Sanxia Water [13] - Tian Cheng Technology canceled the use of 91 million yuan of raised funds for permanent working capital, ensuring no impact on the normal operation of investment projects [24] Group 4 - Baosteel received approval to publicly issue bonds totaling 20 billion yuan to professional investors, valid for 24 months [52] - Tian Kang Biological reported a 10.15% year-on-year increase in pig sales in August, with a total of 263,800 pigs sold [53] - Xinjiang Construction won multiple major projects totaling 4.506 billion yuan, including a 2.4 billion yuan photovoltaic hydrogen synthesis project [18]

Group 1 - The core viewpoint of the news is the performance and financial details of Sanbo Brain Science Hospital Management Group Co., Ltd., which saw a stock price increase of 5.02% to 63.85 CNY per share, with a trading volume of 1.113 billion CNY and a turnover rate of 11.23%, resulting in a total market capitalization of 13.152 billion CNY [1] - Sanbo Brain's main business involves providing medical services, with revenue composition being 74.35% from medical services, 25.02% from pharmaceuticals, 0.39% from other supplementary services, and 0.24% from supply chain [1] - The company was established on November 25, 2003, and went public on May 5, 2023, indicating a relatively recent entry into the public market [1] Group 2 - Southern Fund's Southern CSI 1000 ETF (512100) is among the top ten circulating shareholders of Sanbo Brain, having increased its holdings by 249,800 shares in the second quarter, totaling 1.3295 million shares, which represents 0.83% of the circulating shares [2] - The Southern CSI 1000 ETF has a current scale of 64.953 billion CNY and has achieved a year-to-date return of 26.15%, ranking 1602 out of 4223 in its category, and a one-year return of 65.35%, ranking 1153 out of 3780 [2] - The fund manager, Cui Lei, has been in position for 6 years and 300 days, with the fund's total asset scale at 94.976 billion CNY, achieving a best return of 133.3% and a worst return of -18.12% during the tenure [3]

Group 1 - Company plans to invest 57 million yuan in a new fund focused on brain science, aiming to enhance its clinical diagnosis and technological capabilities [1] - The fund aims to raise a total of 300 million yuan, targeting investments in brain disease diagnostics, treatment, health management, and medical information technology [1] - The fund will prioritize companies with technological breakthroughs and independent intellectual property rights in the brain science sector [1] Group 2 - Other limited partners in the fund include various investment firms with a focus on hard technology and healthcare sectors, indicating a diverse investment base [2] - The fund's profit distribution follows a "return of capital first, then dividends" principle, with an 8% annualized return threshold for limited partners [2] - The company emphasizes that the fund's operations will complement its existing medical, educational, and research capabilities, enhancing its competitive edge in the neurology field [3]